Not for publication or distribution in the United States of America, Australia, Canada, Japan or South Africa or in any other jurisdiction in which offers or sales would be prohibited by applicable law.


Corporate News

Free float in Medios AG increases significantly

Berlin, 26 February 2019 - The free float in Medios AG ('Medios' or 'Company', ISIN: DE000A1MMCC8, WKN: A1MMCC ticker: ILM1), one of the leading Specialty Pharma companies in Germany, increases significantly by 15 percentage points to 55.5 per cent of the voting rights after a successful private placement by the core shareholder mediosmanagement GmbH.

In total, 2,184,603 existing no-par value bearer shares were sold as part of the private placement. This corresponds to around 15 per cent of the share capital. The offer was directed exclusively at institutional investors. Berenberg acted as Sole Bookrunner for the transaction. After the placement, mediosmanagement GmbH and Manfred Schneider (Founder & CEO) hold around 41 per cent of the outstanding shares and have agreed to a 180-day lock-up period.

Matthias Gärtner, CFO of Medios AG: "Medios is benefitting from the successful private placement of our core shareholder threefold: On the one hand, the free float increases, while on the other hand, the liquidity of the shares rises as well. Moreover, our presence in the capital market is being strengthened. Existing as well as potential investors can capitalize on this in the long term."

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients and GMP-certified provider of individualized therapies, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Individualized therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Telephone: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer / Important Note
This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Australia, Canada, Japan or South Africa or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase the above mentioned securities in the United States, Germany or any other jurisdiction.

The securities mentioned above have already been sold. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction.

The securities of Medios AG have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities of Medios AG may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act.